MARKET

INCY

INCY

Incyte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

80.50
-0.12
-0.15%
After Hours: 80.50 0 0.00% 17:45 01/17 EST
OPEN
80.98
PREV CLOSE
80.62
HIGH
81.11
LOW
80.05
VOLUME
1.42M
TURNOVER
--
52 WEEK HIGH
96.79
52 WEEK LOW
72.00
MARKET CAP
17.34B
P/E (TTM)
43.18
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INCY and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

INCY News

  • Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It’s Trying.
  • Barrons.com.4d ago
  • Incyte Stock Is Down: Buy the Dip?
  • MotleyFool.com.4d ago
  • 2 Top Growth Stocks to Buy in January
  • MotleyFool.com.4d ago
  • JMP Securities Maintains Outperform on Incyte, Raises Price Target to $121
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About INCY

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
More

Webull offers Incyte Corporation (INCY) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.